The future of JAK inhibition for MPNs

Описание к видео The future of JAK inhibition for MPNs

Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the future of JAK inhibition for treating myeloproliferative neoplasms (MPNs). Type II JAK inhibition and combination therapies with JAK inhibitor backbones present promising approaches for improving patients' quantity and quality of life. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео